Supplementary information
tumours’
RECURRENCE, PATHOLOGY, INFILTRATION

Supplementary Methods, Supplementary Notes and Supplementary Fig. 1 (the uncropped gels).Reporting SummaryPatient treatment histories (related to the ‘HSV1 serology predicts efficacy’ section).Patient tissue summary and pathology quantifications (related to the ‘CAN-3110 increases T cells in tumours’ and ‘Persistence is linked to seronegativity’ sections).TCR sequences that were statistically changed in TILs after treatment with CAN-3110 (related to the ‘Changes in T cell repertoire’ section).Peer Review FileThe experience of participant 021 with CAN-3110. Participant 021 underwent standard of care surgery and chemoradiation for her GBM, but then recurred. After a second surgery, she recurred rapidly. She then underwent intraoperative MRI-guided stereotactic injection of CAN-3110. An MRI 90 days later appeared to show recurrence again and she underwent a third resection. This resection showed significant new infiltration with CD8